Compare TH & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TH | KALV |
|---|---|---|
| Founded | 1978 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.3M | 757.7M |
| IPO Year | 2017 | 2014 |
| Metric | TH | KALV |
|---|---|---|
| Price | $9.26 | $16.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $11.00 | ★ $30.00 |
| AVG Volume (30 Days) | 459.1K | ★ 797.5K |
| Earning Date | 03-11-2026 | 05-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $320,635,000.00 | $50,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $30.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $5.94 | $9.83 |
| 52 Week High | $9.90 | $19.00 |
| Indicator | TH | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 65.66 | 53.46 |
| Support Level | $7.80 | $14.59 |
| Resistance Level | $9.90 | $17.30 |
| Average True Range (ATR) | 0.41 | 1.11 |
| MACD | 0.07 | -0.05 |
| Stochastic Oscillator | 72.20 | 46.54 |
Target Hospitality Corp is a vertically integrated specialty rental and hospitality services company in the United States. The company provides vertically integrated specialty rental and comprehensive hospitality services including catering food services, maintenance, housekeeping, grounds-keeping, on-site security, overall workforce lodge management, and laundry service. Its operating segment includes HFS-South and HFS-Midwest; Government; TCPL Keystone and others. It generates a majority of its revenue from the Government segment which consists of specialty rental and vertically integrated hospitality services revenue from customers with Government contracts located in Texas.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.